Cleared Traditional

K200272 - Terragene Chemdye (FDA 510(k) Clearance)

Class II General Hospital device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K200272 · Terragene S.A. · General Hospital

Download Printable Device Report (PDF)

Optimized for regulatory review, auditing and printing

Jun 2020

Decision

147d

Days

Class 2

Risk

K200272 is an FDA 510(k) clearance for the Terragene Chemdye. Classified as Indicator, Physical/chemical Sterilization Process (product code JOJ), Class II - Special Controls.

Submitted by Terragene S.A. (Alvear, AR). The FDA issued a Cleared decision on June 30, 2020 after a review of 147 days - within the typical 510(k) review window.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.2800 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the General Hospital review framework, consistent with the majority of Class II 510(k) submissions.

View all Terragene S.A. devices

Submission Details

510(k) Number	K200272 FDA.gov
FDA Decision	Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received	February 04, 2020
Decision Date	June 30, 2020
Days to Decision	147 days
Submission Type	Traditional
Review Panel	General Hospital (HO)
Summary	Statement
Third-party Review	No - reviewed directly by FDA

Regulatory Context

Review time vs. panel average

19d slower than avg

Panel avg: 128d · This submission: 147d

Pathway characteristics

Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code	JOJ Indicator, Physical/chemical Sterilization Process
Device Class	Class 2 - Special Controls
CFR Regulation	21 CFR 880.2800

What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General Hospital devices follow this clearance model.